Sub-$1 stocks sit in a distinctly different regime from the rest of the market — routine 20-50% single-session swings, thin liquidity, and headline-driven volatility define this corner of trading. Here are top penny stocks under $1 carrying genuine near-term catalysts heading into Thursday’s session.

Today’s Market Pulse | A Volatile Backdrop for High-Risk Names

Tuesday’s broader market saw the Dow climb 1.03% to 52,747.32 on strong earnings from Sherwin-Williams and Coca-Cola, while the Nasdaq slipped 0.22% as the semiconductor selloff extended into a fourth straight session. Sub-$1 stocks tend to trade with even less correlation to broad index moves than small caps generally, since company-specific catalysts — FDA decisions, contract wins, reverse-split notices — dominate price action far more than macro sentiment. That dynamic is on full display across this list, where AI data licensing deals, biotech trial data, and Nasdaq compliance notices are driving moves that dwarf anything happening in the S&P 500 this week.

1. Ohmyhome Limited (OMH) | Singapore Proptech Riding a Fresh Rally

The Catalyst

Ohmyhome operates a data and technology-driven property brokerage platform across Singapore and Malaysia, offering listing, valuation, mortgage, and legal conveyancing services through a single app. The stock’s sharp single-day gain reflects the kind of thin-float volatility common among small-cap Southeast Asian proptech names cross-listed on U.S. exchanges.

Why It Matters

As one of the few pure-play property technology stocks trading under $1, OMH’s moves tend to be driven by transaction volume trends in Singapore’s tightly regulated real estate market rather than broader U.S. market sentiment.

2. NextNRG Inc. (NXXT) | An AI-Driven Energy Platform With Real Revenue Growth

The Catalyst

NextNRG’s mobile fueling and microgrid platform posted approximately 44% gross profit growth in June alone, with management noting every month of 2026 has outgrown the prior year by double digits. The company recently commenced pre-construction on California healthcare microgrid projects and provided on-site fuel delivery to generators supporting a major global soccer tournament. Despite the operational momentum, ThinkEquity cut its price target to $1 from $6 while maintaining a Buy rating, while H.C. Wainwright’s Amit Dayal maintained an unchanged $5 target.

Why It Matters

The wide gap between NXXT’s sub-$0.35 share price and analyst targets as high as $5 illustrates how dramatically small-cap energy names can be repriced if execution continues — or how quickly targets can compress if it doesn’t.

3. Golden Sun Education Group (GSUN) | Extreme Volatility in Chinese Ed-Tech

The Catalyst

Golden Sun Education’s sharp reversal reflects the extreme volatility common among small-float, U.S.-listed Chinese education technology names, where daily percentage swings routinely dwarf those of domestic penny stocks.

Why It Matters

Stocks like GSUN illustrate the liquidity risk inherent in the sub-$1 universe — a name can be among the day’s top gainers one session and a top decliner the next, often without a specific company-level catalyst driving either move.

4. China SXT Pharmaceuticals (SXTC) | A Cautionary Tale in Sub-$0.10 Trading

The Catalyst

China SXT Pharmaceuticals’ collapse to just six cents a share, following an over 80% single-day decline, places it firmly in the sub-$0.10 tier where bid-ask spreads alone can run 10-30% — a level where liquidity risk often overwhelms any underlying business fundamentals.

Why It Matters

SXTC is a textbook example of why sub-$1, and especially sub-$0.10, stocks warrant extreme caution: at this price tier, a stock can lose the vast majority of its remaining value in a single session with limited ability for holders to exit at a favorable price.

5. CleanCore Solutions (ZONE) | An Aqueous Ozone Company Pivoting Into AI Data Centers

The Catalyst

CleanCore, historically a cleaning-technology company built around patented aqueous ozone systems, announced its first data center project: a Tier 3-standard AI campus delivering approximately 55 MW of utility power capacity and 40 MW of critical IT load under a 10-year colocation services agreement. The pivot represents a dramatic strategic shift for a company whose FY2025 revenue was just $2.07 million against losses of $6.74 million.

Why It Matters

CleanCore’s data center pivot is emblematic of a broader trend among small-cap companies repositioning toward AI infrastructure themes — a move that can dramatically re-rate a stock’s valuation if executed, but also introduces significant execution risk for a company with limited prior experience in power infrastructure.

6. Worksport Ltd. (WKSP) | A Highly-Rated Small Cap According to Alternative Data

The Catalyst

Worksport, which designs truck bed covers and solar-integrated accessories, ranks among the top-scored names in AltIndex’s penny stock screener, which combines over 10,000 alternative-data and financial signals including hiring trends, web traffic, and insider transactions to separate improving small-cap stories from pure speculation.

Why It Matters

Despite carrying a relatively high AI-driven quality score, Worksport is down roughly 69% over the trailing six months — a reminder that even “better fundamentals” penny stocks have delivered steep losses across this asset class over the past half-year.

7. AuthID Inc. (AUID) | A Biometric Identity Play With the Sector’s Top Score

The Catalyst

AuthID provides biometric identity verification technology, positioning it within the growing digital identity and fraud-prevention space. The stock is down approximately 40.4% over the trailing six months despite its relatively strong alternative-data score, underscoring how difficult the broader penny stock environment has been in 2026 even for names with improving underlying signals.

Why It Matters

As identity verification becomes increasingly critical for fintech, healthcare, and AI platforms verifying human users, AuthID’s technology addresses a genuine and growing market need — the question for sub-$1 investors is whether the company can translate that need into revenue before running low on capital.

8. Tenaya Therapeutics (TNYA) | Gene Therapy Data Offers a Binary Catalyst

The Catalyst

Tenaya, a clinical-stage cardiovascular gene therapy company, reported interim results from its RIDGE-1 trial showing its TN-401 gene therapy led to consistent, durable reductions in arrhythmia burden in PKP2-associated ARVC patients, with biopsies confirming robust gene delivery. The company also ended a manufacturing center lease as part of a broader strategic shift and appointed a new CFO in late June.

Why It Matters

The gap between Tenaya’s sub-$1 share price and its unchanged $5 analyst price target reflects the binary nature of clinical-stage biotech investing — a name trading this far below sell-side targets typically signals either a genuine value opportunity or well-founded skepticism about execution risk, and Thursday’s broader market volatility could sharpen that divide further.

9. OneMedNet Corporation (ONMD) | Fresh $11.5 Million AI Data Deal

The Catalyst

OneMedNet, a healthcare real-world data platform powered by Palantir Foundry, announced Tuesday it entered into an agreement valued at more than $11.5 million to supply regulatory-grade healthcare data for foundational AI model development. The deal follows a strong 2025 in which real-world data revenue grew 329% year-over-year and total liabilities were cut 74%. Shares had rallied 33% after hours on the initial announcement before giving back gains Wednesday.

Why It Matters

OneMedNet’s network now spans over 90 million patient journeys and 270 million studies across more than 2,130 provider sites — scale that positions the company as a legitimate supplier to the AI training data economy, even as its sub-$1 share price reflects a company still working through a history of shareholder dilution and liabilities.

Quick-Reference Table: Today’s Top 10 Penny Stocks Under $1

Sector Sentiment Snapshot and Forecast

The theme running through this week’s most active sub-$1 names is AI infrastructure and data — NextNRG’s microgrids, CleanCore’s data center pivot, and OneMedNet’s foundational model data deal all reflect small-cap companies repositioning toward the same AI buildout theme driving mega-cap valuations, just at a fraction of the market cap and with dramatically higher execution risk. Biotech names like Tenaya and BiomX continue trading on binary clinical catalysts largely disconnected from broader market sentiment, while names like Golden Sun and China SXT Pharmaceuticals serve as reminders of how quickly capital can exit thin-float sub-$1 stocks. As always with this category, position sizing and liquidity awareness matter as much as the underlying story — spreads and volatility at this price tier can erase paper gains before they’re realized.

Follow TNN for daily stock market news and financial news today.

Disclaimer: This publication is entirely for informational and journalistic purposes and does not constitute formal financial, investment, or legal advice. All market investments carry inherent risks of capital loss. Always complete independent due diligence prior to executing equity trades.

About The Author

Kasia Davis

See author's posts